Data Dictionary: Pancreatic cancer - DPCA: Difference between revisions
From Beacon
No edit summary |
No edit summary |
||
| Line 16: | Line 16: | ||
* Weight loss in kg and period in weeks | * Weight loss in kg and period in weeks | ||
* ECOG performance status (Eastern Cooperative Oncology Group) | * ECOG performance status (Eastern Cooperative Oncology Group) | ||
Laboratory Biomarkers | Laboratory Biomarkers | ||
| Line 24: | Line 25: | ||
* Carcinoembryonic antigen (CEA) in µg/l | * Carcinoembryonic antigen (CEA) in µg/l | ||
* CA19.9 in kU/l (Note: Last CA19.9 before the start of neoadjuvant treatment or surgery) | * CA19.9 in kU/l (Note: Last CA19.9 before the start of neoadjuvant treatment or surgery) | ||
Imaging and Diagnostic Procedures | Imaging and Diagnostic Procedures | ||
| Line 31: | Line 33: | ||
* Cystic features suggestive of malignancy | * Cystic features suggestive of malignancy | ||
* Involvement of vessels and other structures on imaging | * Involvement of vessels and other structures on imaging | ||
Histology and Cytology | Histology and Cytology | ||
| Line 36: | Line 39: | ||
* Method and date of obtaining the first positive cytology or histology | * Method and date of obtaining the first positive cytology or histology | ||
* Histological and cytological diagnoses | * Histological and cytological diagnoses | ||
Multidisciplinary Team Consultations and Decisions | Multidisciplinary Team Consultations and Decisions | ||
* Date of the last MDT (Multidisciplinary Team) discussion before treatment | * Date of the last MDT (Multidisciplinary Team) discussion before treatment | ||
* Working diagnosis and eligibility for surgical exploration | * Working diagnosis and eligibility for surgical exploration | ||
Treatment and Surgery Details | Treatment and Surgery Details | ||
| Line 45: | Line 50: | ||
* Operative details including ASA score, type of resection, and operative complications | * Operative details including ASA score, type of resection, and operative complications | ||
* Postoperative pathology including tumor origin, size, and grade | * Postoperative pathology including tumor origin, size, and grade | ||
Postoperative Management and Follow-Up | Postoperative Management and Follow-Up | ||
Revision as of 21:26, 8 May 2024
Go back to Dutch Institute for Clinical Auditing Databases (DICA) (The Netherlands) page.
This is a summary of the variables available in the database. You can download the complete data dictionary. [Click here to learn more.
Comorbidities
Patient Identification and Treatment Timeline
- Treatment start date
- Reason for registration
- Hospital patient number
Patient Physical and Performance Metrics
- Height in cm
- Preoperative weight in kg
- Weight loss in kg and period in weeks
- ECOG performance status (Eastern Cooperative Oncology Group)
Laboratory Biomarkers
- Bilirubine in µmol/l
- Hemoglobine in mmol/l
- Albumine in g/l
- IgG4 in g/l
- Carcinoembryonic antigen (CEA) in µg/l
- CA19.9 in kU/l (Note: Last CA19.9 before the start of neoadjuvant treatment or surgery)
Imaging and Diagnostic Procedures
- CT, MRI, or MRCP performed
- Date of the last preoperative imaging
- Presence of a tumor in the pancreas or periampullary on CT or MRI
- Cystic features suggestive of malignancy
- Involvement of vessels and other structures on imaging
Histology and Cytology
- Preoperative PA number
- Method and date of obtaining the first positive cytology or histology
- Histological and cytological diagnoses
Multidisciplinary Team Consultations and Decisions
- Date of the last MDT (Multidisciplinary Team) discussion before treatment
- Working diagnosis and eligibility for surgical exploration
Treatment and Surgery Details
- Neo-adjuvant/induction treatment type and start date
- Operative details including ASA score, type of resection, and operative complications
- Postoperative pathology including tumor origin, size, and grade
Postoperative Management and Follow-Up
- Palliative treatments including chemotherapy and radiotherapy
- Date of discharge and any readmissions within 30 days
- Adjuvant therapy details and participation in oncological trials
